# Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer

> **NCT07224022** · PHASE2 · NOT_YET_RECRUITING · sponsor: **John Strickler, M.D.** · enrollment: 24 (estimated)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]

## Key facts

- **NCT ID:** NCT07224022
- **Lead sponsor:** John Strickler, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-08-31
- **Final completion:** 2029-11-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224022, "Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07224022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*